Boundless Bio
BOLD | NASDAQ
$2.41
-$0.09 (-3.60%)
At close: Nov 16, 2026, 4:00 PM ET
$2.39
-$0.02 (-0.83%)
After-hours:
Nov 16, 2026, 6:23 PM ET
-3.60%
(1D)No price chart data available for 1D timeframe.
Rating
28.2
+1.4 ptsFundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #837/1021 (Top 82%)
Key Statistics
Market Data
Market Cap $56.9M
1D Range
2.40 2.50
52W Range
1.05 3.00
Valuation (TTM)
PE -0.98
PB 0.92
EV/EBITDA 0.11
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $0.00
Cash Flow
FCF Yield -100.9%
SBC Adj. FCF Yield -111.8%
SBC Impact -10.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 5.2% |
-20.3%
FCF 3Y | 5Y 1.7% |
-22.1%
Returns
ROA -87.3%
ROE -71.0%
ROIC -95.7%
Financial Health
Net Cash
$62.89M
Current Ratio 33.97
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Th...
Sector Healthcare
Industry Biotechnology
Employees 28
IPO Date Mar 28, 2024
Website boundlessbio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Add to Watchlist
Select watchlists to add or remove BOLD